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Abstract
Background: Gastrointestinal stromal tumors (GIST) mutational status is recognized factor related to the results of
tyrosine kinase inhibitors therapy such as imatinib (IM) or sunitinib (SU). Arterial hypertension (AH) is common adverse
event related to SU, reported as predictive factor in renal cell carcinoma. The aim of the study was to analyze the
outcomes and factors predicting results of SU therapy in inoperable/metastatic CD117(+) GIST patients after IM failure.
Methods: We identified 137 consecutive patients with advanced inoperable/metastatic GIST treated in one center
with SU (2nd line treatment). Median follow-up time was 23 months. Additionally, in 39 patients there were
analyzed selected constitutive single nucleotide polymorphisms (SNPs) of VEGFA and VEGFR2 genes.
Results: One year progression-free survival (PFS; calculated from the start of SU) rate was 42% and median PFS
was 43 weeks. The estimated overall survival (OS, calculated both from start of SU or IM) was 74 weeks and 51
months, respectively. One-year PFS was 65% (median 74 weeks) in 55 patients with AH vs. 22% (median 17 weeks)
in patients without AH. Patients with primary tumors carrying mutations in KIT exon 9 or wild-type had
substantially better 1-year PFS (68% and 57%; median 65.5 and 50.5 weeks, respectively) than patients having
tumors with KIT exon 11 or PDGFRA mutations (34% and 15%; median 36.8 and 9 weeks, respectively). We
identified two independent factors with significant impact on PFS and OS in univariate and multivariate analysis:
primary tumor genotype and presence of AH. The most common adverse events during therapy were: fatigue, AH,
hypothyroidism, hand and foot syndrome, mucositis, skin reactions, dyspepsia, and diarrhea. Two deaths were
assessed as related to tumor rupture caused by reaction to SU therapy. The presence of C-allele in rs833061 and
the T-allele in rs3025039 polymorphism of VEGFA were associated with significantly higher risk of hypothyroidism
(OR: 10.0 p = 0.041 and OR: 10.5; p = 0.015, respectively).
Conclusions: We confirmed that many advanced GIST patients benefit from SU therapy with OS > 1.5 year.
Primary tumor KIT/PDGFRA genotype and SU-induced AH, as surrogate of its antiangiogenic activity are two
independent factors influencing both PFS and OS.
Note: The preliminary data of this study were presented during Annual Meeting of American Society of Clinical
Oncology, 4-8 June 2011 and Connective Tissue Oncology Society Meeting, 26-28 October 2011 in Chicago, IL.
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Background
Unprecedented improvement in advanced gastrointest-
inal stromal tumors (GIST management has been
achieved due to recent recognition of the important bio-
logical role of activating mutations in KIT and PDGFRA
(platelet-derived growth factor receptor- alpha) genes.
Those observations led to the introduction of imatinib
mesylate, a small-molecule selective inhibitor of the
receptor tyrosine kinases such as stem-cell factor recep-
tor (KIT, CD117), BCR-ABL and platelet-derived growth
factor receptors (PDGFRs)-A and -B. Imatinib revolutio-
nized the outcome of patients with advanced CD117-
positive GISTs and is currently approved as the first-line
treatment in advanced (metastatic and/or inoperable)
GISTs [1-5]. However, the spectacular response to ima-
tinib therapy is time-limited and secondary resistance to
imatinib therapy (after initial stabilization or response)
develops in majority of patients [4].
Currently, the only approved second-line drug is suni-
tinib malate - a multitargeted agent, an inhibitor of tyro-
sine kinase, of KIT and PDGFRA/B and of the vascular
endothelial growth factor receptors (VEGFRs)-1, -2 and
3, FMS-like tyrosine kinase-3 (FLT3), colony stimulating
factor 1 receptor (CSF-1R), and glial cell-line derived
neurotrophic factor receptor (REarranged during Trans-
fection; RET) [6-11]. Sunitinib possesses both antiangio-
genic and cytostatic properties and by competing with
ATP binding prevents multiple receptor tyrosine kinases
phosphorylation in vitro and in vivo. Two phase II, one
phase III and one “treatment-use” trials have investi-
gated the activity of sunitinib in GIST patients after the
failure of prior imatinib treatment, and all these trials
have shown the significant activity of sunitinib in this
population of patients [11-14]. The objective clinical
benefit was achieved in approximately 60% of GIST
patients who received sunitinib after failure of prior
imatinib treatment [11-14]. Median progression -free
survival time on sunitinib is 6-8 months. The adverse
events reported during this therapy are frequent. The
most common treatment-related adverse events were
fatigue, diarrhea, skin discoloration, nausea, mucositis,
arterial hypertension, hand and foot syndrome (palmar-
plantar erythrodysesthesia), impairment of left ventricu-
lar ejection fraction and hypothyroidism [12,14].
Moreover, arterial hypertension was not only the com-
mon adverse event during sunitinib therapy, but it was
reported as predictive factor for results of renal-cell car-
cinoma (RCC) patients [15,16]. This phenomenon has
not been yet analyzed in GIST patients.
There is a lack of studies analyzing the outcome of
sunitinib in advanced GISTs after imatinib failure ther-
apy in routine practice outside clinical trials. Thus, the
aim of our study was to evaluate factors predicting
results and toxicity of SU second-line therapy in inoper-
able/metastatic GISTs. Additionally, we have investi-
gated the impact of the selected single nucleotide
polymorphisms (SNPs) in VEGFA and VEGFR2 genes
on sunitinib-related toxicity in the subgroup of patients.
Patients and Methods
Patients
We analyzed prospectively collected data of 137 conse-
cutive patients treated with sunitinib maleate because of
inoperable and/or metastatic CD117 positive GIST
enrolled into therapy between October, 2005 and Febru-
ary, 2011, reviewed in one tertiary cancer center. All
patients met the following criteria for sunitinib treat-
ment: 1) histological diagnosis of GIST, confirmed by
CD117-immunopositivity (DAKO; Carpintiera, CA), 2)
metastatic and/or inoperable lesions after failure on
prior treatment with imatinib (confirmed progressive
disease or unacceptable toxicity) 3) measurable disease
on computed tomography (CT) scans, 4) WHO perfor-
mance status ≤3, 5) no concomitant therapy for disease,
6) adequate renal, cardiac and liver function.
Each patient provided informed consent for the study
and collection of clinical and molecular data prior suni-
tinib therapy. The study had been approved by the local
Bio-Ethics Committee according to Good Clinical Prac-
tice Guidelines (approvals from Bio-Ethics Committees
from Medical University of Gdansk and from Maria
Sklodowska-Curie Memorial Cancer Center and Insti-
tute of Oncology, Warsaw KB/9/2011 and approval for
Polish Clinical GIST Registry by Internal Review Board
119/2002). Patients provided additional informed con-
sent for taking the 5 ml blood samples for gene poly-
morphisms analysis. Patients did not undergo any
further selection; 35 patients were initially included in
the treatment-use trial A6181036.
All patients were treated with sunitinib in initial
licensed dose of 50 mg daily in 6 weeks cycle (4 weeks
on/2 weeks off therapy), however the dosing could be
reduced (to 37.5 mg or 25 mg) or delayed or modulated
to the dosing of 37.5 mg on continuous schedule to
optimize the benefit-risk profile according to decision of
treating physician. The treatment was continued until
confirmed progression of the disease or unacceptable
toxicity. All patients were followed carefully with med-
ian follow-up time of 23 months (range: 6-68 months).
The objective response of GIST to sunitinib therapy was
evaluated with serial CT examinations (performed every
2-3 months), according to Response Evaluation Criteria
in Solid Tumors (RECIST) version 1.0 [17]. In case of
progression, patients were treated with other different
tyrosine kinase inhibitors or cytotoxic chemotherapy or
best supportive care only. If possible, they were included
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into clinical trials with new compounds. Toxic effects
were graded with National Cancer Institute common
toxicity criteria, version 3.0 [18].
Genotyping
Genomic screening was performed for the presence of
the KIT (exons 9, 11, 13, and 17) or PDGFRA (exons 12,
14 and 18) genes mutation in randomly selected 89
cases, based on DNA isolated from paraffin-embedded
or fresh frozen imatinib-naive tumor tissues, as pre-
viously described [19].
SNPs analysis
Genomic DNA was isolated from peripheral blood sam-
ples of 39 consenting patients using the standard proto-
col with proteinase K digestion, phenol - chloroform
extraction and ethanol precipitation. Three selected
VEGFA SNPs: rs699947 (-2578 C > A), rs3025039 (+936
C > T), and rs2010963 (+405 G > C) and two VEGFR2
(KDR) SNPs: rs1531289 (3405-92A > G) and rs1870377
(+1416 T > A) were genotyped using restriction frag-
ment length polymorphism (RFLP) method. The restric-
tion enzymes which detected - SNPs mentioned above
were BsaIII, BsmF1, NlaIII and AluI, respectively.
Amplified DNA was digested with endonucleases over-
night at optimal temperatures according to the manu-
facturer (Fermentas, Thermo Scientific) and then
electrophoresed on 2% agarose gel. For identification of
an additional VEGFA SNP: - rs833061 (460 T > C)
direct sequencing was performed using ABI 3100
Genetic Analyser (Applied Biosystems Inc. Foster City,
CA). Primers sequences and PCR cycling parameters are
available on request.
Statistical analysis
Contingency tables were analyzed by the chi-square test.
Progression-free survival (PFS) time was calculated from
the date of the start of sunitinib treatment to the date
of the most recent follow-up, or progression or death
due to the disease. Overall survival (OS) time was calcu-
lated either from the date of the start of imatinib and
sunitinib treatment to the date of the most recent fol-
low-up or death due to the disease [except cases of two
patients, whose death was attributed to adverse event
(AE) of sunitinib therapy]. PFS was assessed with respect
to the following variables: demographic data (age at the
diagnosis ≤ 45 or > 45 years; gender), primary tumor
genotype (KIT 11 exon, KIT 9 exon, any PDGFRA muta-
tions and wild-type cases), length of previous therapy on
imatinib (≤ 6, > 6-12, > 12 months), and presence of
arterial hypertension (defined as occurrence of systolic
blood pressure > 140 mm Hg or diastolic blood pressure
> 90 mm Hg, or deterioration of preexisting AH during
the first three months of therapy with sunitinib). The
Kaplan-Meier method was used for analysis of survival
curves, compared by log-rank test.
For univariate comparison of the survival between
groups, the Kaplan-Meier estimator was used with gen-
eralized Wilcoxon and the log-rank tests. For PFS/OS
comparisons in relation to presence of arterial hyperten-
sion two cases with early death due to tumor perfora-
tion were excluded to minimize the lead-time bias of
the results. In multivariate analysis of the factors asso-
ciated with PFS and OS, we used Cox proportional
hazards models, applying the stepwise model building
procedure that included all covariates significant at 20%
level in bivariate analysis. Two-way interactions were
then considered in the model. Differences were consid-
ered statistically significant if p-values were < 0.05.
These statistical computations were performed using
Statistica 6.1 software [Statsoft®; Tulsa, OK].
The Hardy-Weinberg equilibrium analysis of VEGFA
and VEGFR2 polymorphisms was performed using a
chi-square test with one degree of freedom. Multiplica-
tive, dominant and recessive models were tested in
every SNP for the associations with OS, PFS and treat-
ment AEs. Odds ratios (ORs) with their exact 95% con-
fidence intervals (CI) were calculated and the exact test
for OR was used. The polymorphisms analyses were
performed using StatXact-3 software, version 3.1.
Results
Clinicopathological data
The distribution of clinical and pathological data of
patients included in the study is listed in Table 1. There
were 74 male and 63 female patients, with median age
at the start of sunitinib therapy 55 years (range: 15 -
82). The majority of primary tumors were located in the
small intestine (57.6%), followed by the stomach (33.5%).
All but two patients had documented progression on
imatinib. Majority of patients (70.1%) were pre-treated
with imatinib for more than one year. Almost 90% of
patients started sunitinib therapy being in relatively
good performance status (0-1).
Mutational analysis data
The distribution of patients according to the initial
tumor mutational status is shown in Table 1. In the
group of 89 patients, whose initial tumor mutational sta-
tus was evaluated, 58.4% of GISTs had an exon 11 KIT
mutation, 16.9% had an exon 9 KIT mutation, 13.5%
had PDGFRA gene mutation (11 of 12 cases had D842V
mutation) and in 11.2% of tumors we have not detected
any mutations (wild-type).
Treatment toxicity
Adverse events were common during sunitinib treat-
ment (127/137 evaluated patients; 93%), and in 31.4% of
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patients they were assessed as grade 3/4 (Table 2). The
most common non-hematological adverse events were:
fatigue (65%), arterial hypertension (43%), hand-foot
syndrome (40%), hypothyroidism (31%), skin/hair disco-
loration (30%), diarrhea (28%) and mucositis (25.5%).
The frequency of reported hematological toxicity was as
follows: anemia (37%), neutropenia (36%) and thrombo-
cytopenia (13%). Two deaths (grade 5) due to the tumor
rupture and hemorrhage were assessed as related to
reaction to sunitinib therapy (during 1st month of ther-
apy). Additionally, three patients were operated due to
tumor perforation (bleeding/bowel perforation) also
attributed to reaction to sunitinib. For management of
drug toxicity sunitinib dose was reduced to 37.5/25 mg
in 44% of cases (60 patients).
Outcomes of sunitinib treatment
Median PFS was 43 weeks and estimated 1-year PFS
rate was 42%. Progression of disease during sunitinib
therapy was observed in 105 cases (77%). At the time of
the analysis, 45 patients (33%) were alive. Estimated 2-
year OS rate was 40% and median OS was 73.5 weeks.
Estimated 5-year OS in this group of patients was 45%
(when calculated from the date of imatinib start) and
median OS - 51 months.
The best responses observed during sunitinib therapy
and estimated by CT imaging (two consecutive exami-
nations) according to RECIST criteria were as follows:
none complete responses (CRs), 21 (15%) partial
responses (PRs), 62 (45%) stable disease (SD) at least
four months, 51 (37%) progressive disease (PD) and
three patients were not assessable for response. Overall
clinical benefit of sunitinib therapy (counted as the sum
of CR, PR and SD rates) was 60%.
Correlations between mutational status of primary GISTs
and response to sunitinib therapy
We have found a strong relationship (p < 0.001)
between the primary tumor genotype and best observed,
confirmed response to sunitinib according to RECIST
criteria: the best outcomes were observed for KIT exon
9 mutants (six PR - 40%, seven SD - 47%, two PD -
13%), followed by wild-type GISTs (seven SD - 70% and
three PD - 30%) and KIT exon 11 mutants (10 PR -
19%, 23 SD - 44%, 19 PD - 37%); the worst results of
sunitinib therapy were found in patients with PDGFRA
mutated GISTs (two SD - 17% and 10 PD - 82%).
Factors influencing PFS and OS during sunitinib therapy
In univariate analysis two factors significantly correlated
with shorter PFS and OS that were: tumor genotype:
exon 11 KIT or PDGFRA mutation (p = 0.04 and p =
Table 1 Characteristics of 137 patients treated with
sunitinib due to advanced GIST
Clinicopathological
features
No of
patients
(%)
Total number of patients 137 (100)
Age [years] at the start of
therapy with sunitinib
Median (range) 55 (15-82)
≤45 14 (10)
> 45 123 (88)
Gender Female 63 (46)
Male 74 (54)
Primary tumor site Stomach 46 (33.5)
small bowel 79 (57.6)
large bowel/rectum 4 (2.9)
other or intraperitoneally with
unknown primary origin
8 (5.8)
Time on imatinib therapy ≤ 6 months (early resistance) 25 (18.2)
6-12 months 16 (11.7)
> 12 months 96 (70.1)
Primary reason for stop of
imatinib therapy
Disease progression 135 (98.5)
Imatinib intolerance 2 (1.5)
ECOG Performance Status 0 48 (35)
1 72 (52.6)
≥2 17 (12.4)
Tumor genotype* Exon 11 KIT mutation 52 (58.4)
Exon 9 KIT mutation 15 (16.9)
PDGFRA mutation 12 (13.5)
Wild-type 10 (11.2)
Data not available 48
* mutational status was evaluated in 89 cases (65%)
Table 2 The most common adverse events (AEs) during
sunitinib therapy in the entire analyzed group of GIST
patients
Any grade Grade 3/4
AEs n % N %
Any treatment-related AE 127 92.7 43 31.4
Fatigue 89 65 12 8.7
Diarrhea 37 28 4 2.9
Hand-foot syndrome 55 40 3 2.2
Decreased appetite/dysgeusia 25 18.2 0 0
Mucositis 35 25.5 2 1.5
Hypertension 59 43 4 2.9
Neutropenia 49 36 7 5.1
Anemia 51 37 8 5.8
Skin/hair discoloration 41 30 0 0
Dyspepsia 43 31.4 0 0
Thrombocytopenia 18 13.1 3 2.2
Hypothyroidism 42 31 2 1.5
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0.04, respectively) (Figure 1), and absence of arterial
hypertension during sunitinib therapy (p = 0.0001 and p
= 0.001) (Figure 2). We did not find any significant cor-
relation between PFS/OS and patients gender and age at
diagnosis, GIST primary tumor location, WHO perfor-
mance status 0 vs. 1, or time on previous imatinib treat-
ment. Estimated 1-year PFS and 2-year OS according to
primary tumor genotype were as follows: KIT exon 9
mutations - 68%/73% (median 65.5/151.5 weeks), wild
type - 57%/70% (median 50.5/121 weeks), KIT exon 11
mutations - 34%/34% (median 36.8/65.5 weeks) and
PDGFRA mutations - 15%/25% (median 9/40 weeks).
Patients with presence of arterial hypertension during
first three months of sunitinib therapy had substantially
better 1-year PFS and 2-year OS than patients without
this adverse event (65% vs. 22%, and 63% vs. 18%; med-
ian 77 vs. 25.5 weeks, and 128.5 vs. 43 weeks,
respectively).
In the multivariate analysis two factors (tumor geno-
type and arterial hypertension) had independent predic-
tive value for PSF and OS (Tables 3 and 4).
Genetic variations of VEGFA and VEGFR2 genes
The genotype frequency of VEGFA/VEGFR2 gene SNPs
are presented in Table 5. All analyzed genotypes were in
Hardy-Weinberg equilibrium. The higher risk of
hypothyroidism during sunitinib therapy was associated
with: C-allele in rs833061 (OR: 10.l; p = 0.041) and T-
allele in rs3025039 (OR: 10.5; p = 0.015) (Table 6). We
did not find the correlation between the presence of
SNPs and arterial hypertension, hand-foot-syndrome,
skin toxicity/mucositis or diarrhea (data not shown).
Discussion
A majority of patients with advanced GISTs ultimately
stop responding to imatinib and unquestionably
management of disease resistant to first-line treatment
represents a clinical challenge [4]. Insights into resis-
tance mechanisms have allowed developing several stra-
tegies in patients with progression during imatinib
treatment. In case of generalized progression (or intoler-
ance to imatinib) the main option is using monotherapy
with alternative multi-tyrosine kinase inhibitor - suniti-
nib, which remains the only approved second line drug
for the treatment of advanced GISTs after imatinib ther-
apy failure [20]. Sunitinib has demonstrated robust clini-
cal effectiveness in imatinib-resistant or -intolerant
GIST as shown in randomized, placebo-controlled phase
III trial in which the median time to tumor progression
for patients treated with sunitinib was more than four
times longer than that for patients receiving placebo
(27.3 vs. 6.4 weeks) [12]. Present study, according to our
best knowledge, represents of the largest series of GIST
patients after imatinib failure analyzed for the outcome
of sunitinib treatment in routine clinical practice outside
randomized, controlled clinical trial.
We have also attempted to prove tumor genotype
implications and to find new predictive factors in this
group of patients. We have confirmed that many
Figure 1 Overall survival during sunitinib therapy according to
primary tumor mutational status.
Figure 2 Progression-free survival during sunitinib therapy
according to presence of arterial hypertension.
Table 3 Multivariate analysis of prognostic factors for
progression-free survival
Hazard
ratio
95% CI Standard
Error
z p
value
Arterial
hypertension
Yes
0.2025 0.1097 -
0.3739
0.0633 -5.11 0.000
Primary tumor
mutation Wild
type
0.3292 0.1447 -
0.7491
0.1381 -2.65 0.008
PDGFRA
mutation
1.8753 0.9096 -
3.8661
0.0692 1.70 0.049
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advanced GIST patients benefit from sunitinib therapy
(mainly due to stabilization of disease according to
RECIST, not Choi criteria [21]) with OS exceeding 1.5
years. The median PFS longer than seven months is
almost equal to the results of the Korean one-institu-
tion study [22]. We have also confirmed in more
detailed way and on the larger group of patients, than
ever published, data regarding the correlation between
primary tumor mutational status and sunitinib treat-
ment outcomes [22-24]. As for imatinib, KIT mutation
status appears to serve as a predictor of tumor
response to sunitinib. We have proven that, contrary
to imatinib, tumors initially (pre-imatinib treatment)
bearing KIT exon 9 mutation or with wild-type geno-
type have a higher chance to respond to sunitinib.
Moreover, GISTs harboring KIT exon 9 mutations
appear to be more sensitive to sunitinib than those
with primary KIT exon 11 mutations (however we
have observed some objective responses also in this
group of patients). The clinical benefit of sunitinib in
wild-type cases is also clear. We have not observed any
response to sunitinib in group of patients with
PDGFRA mutations (mainly D842V), which has been
also shown in preclinical data. We did not analyze the
impact of secondary mutations, although patients from
clinical trials with tumors harboring a secondary muta-
tion in exon 13 or exon 14 KIT have a longer PFS
than patients with exon 17 or 18 mutations [23,25-27].
On the other hand, utility of analysis of secondary
mutations is very challenging because imatinib-
resistant GISTs are very heterogeneous with multiple
clones having different secondary mutations within the
same or different nodules [28-30].
Sunitinib therapy is associated with several adverse
events, which were generally mild to moderate and could
be managed by dose modulation (including continuous
administration of lower dose) [20,22,24]. The toxicity
profile reported in our study is similar to that observed
in clinical trials, with exception of hypothyroidism, which
occurred in more than 30% of patients (it has been
reported outside clinical trials [31,32]). However, up to
one third of cases were classified as more severe toxicity
(and two deaths due to tumor hemorrhage were classified
as related to sunitinib therapy). Our own experience with
patients with unresectable or metastatic GISTs, treated
with tyrosine kinase inhibitors, suggested the higher inci-
dence of emergency operations for gastrointestinal bleed-
ing, bowel obstruction, or abscess, occur during second-
line therapy with sunitinib than during first-line therapy
with imatinib [33,34]. This increased incidence of compli-
cations leading to surgical interventions with sunitinib
could be associated with the presence of more advanced
and drug-resistant disease, or to the direct mechanism of
action of sunitinib, i.e., the combination of cytotoxic and
antiangiogenic activity, leading to dramatic tumor
response.
Arterial hypertension is one of the most common com-
plications of sunitinib therapy, occurring usually early
after treatment initiation. Serial monitoring of blood pres-
sure is recommended during therapy with sunitinib.
Table 4 Multivariate analysis of prognostic factors for overall survival
Hazard ratio 95% CI Standard Error z p value
Primary tumor
mutation Exon 9 KIT mutation
0.7491 0.3308 - 1.6968 0.3125 -0.69 0.489
PDGFRA mutation 1.2678 0.5487 - 2.9327 0.5425 0.55 0.579
Wild-type 0.1029 0.0317 - 0.3336 0.0618 -3.79 0.000
Arterial hypertension
Yes
0.2056 0.1006 - 0.4201 0.0749 -4.34 0.000
CI confidence interval
Table 5 The genotype frequency of VEGFA/VEGFR2 genes SNPs and Hardy-Weinberg equilibrium (HWE) test results
Polymorphism rs number Genotype (%) HWE exact p value Frequency of risk allele
Homozygous (wild) Heterozygou Homozygous (mutant)
VEGFA
-2578 C > A rs699947 32.4 54.1 13.5 0.73 0.41
-460 T > C rs833061 29.7 45.9 24.3 0.74 0.47
936 C > T rs3025039 75.7 24.3 - 1.00 0.12
405 G > C rs2010963 24.3 40.5 35.1 0.32 0.55
VEGFR2 (= KDR)
3405-92A > G rs1531289 48.6 45.7 5.7 0.69 0.29
1416 T > A rs1870377 53.1 40.6 6.3 1.00 0.27
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Sunitinib-induced arterial hypertension may also serve as
biomarker of antitumor efficacy (probably by antiangio-
genic mechanism), because it was an independent factor
influencing patient both progression-free and overall sur-
vival. Antiagiogenic activity may play an important role
in therapy of sarcomas, what has been recently confirmed
by positive results of phase III trial with pazopanib in
pre-treated soft tissue sarcoma patients [35]. Similar rela-
tionships between arterial hypertension induced by VEGF
inhibitors (including sunitinib) and oncological outcomes
have been reported in renal cell carcinoma patients
[15,16,36-39]. Treatment-induced persistent hypertension
was associated with frequent tumor response, a long time
to disease progression and longer overall survival [39].
Clinical outcomes are not compromised by treatment
with anti-hypertension medications, moreover, patients
who required at least three antihypertensive drugs had
the longest PFS and OS [38]. There are proposed some
hypothetical mechanisms leading to hypertension related
to sunitinib, e.g. presence of less-perfused microvessels
and/or diminished number of microvessels, decreasing
nitric oxide production and activation of the endothelin-1
pathway leading to vasoconstriction [40,41].
In the subgroup of patients we have analyzed some
possible pharmacogenetical relationships with sunitinib
tolerance. It has been shown that single nucleotide poly-
morphisms of VEGF and VEGFR2 genes has some
potential as biomarkers for clinical outcomes and toxi-
city of VEGF pathway targeted therapy [42-46]. We
have not studied correlation between SNPs of VEGFA/
VEGFR genes and outcomes of therapy due to limited
number of cases, but we have found clear associations
between two SNPs of VEGFA gene and sunitinib-
induced hypothyroidism. The molecular mechanisms of
hypothyroidism induced by sunitinib are unknown, but
recent studies have suggested that VEGFR inhibition
can induce vasculature regression in various organs, pre-
dominantly in thyroid, what can be linked to different
properties of VEGF protein caused by gene polymorph-
isms and sunitinib sensitivity [47,48].
Conclusions
To summarize, we confirmed that many advanced GIST
patients benefit from sunitinib therapy with overall survi-
val exceeding 1.5 year. Exploring the toxicity of multi-
kinase targeting agents in GISTs may allow better
adjusted therapy as well as to define novel pharmacody-
namics markers. Primary tumor genotype and sunitinib-
induced arterial hypertension (as surrogate of its antian-
giogenic activity) are two independent factors influencing
the progression-free survival and OS. The mechanism of
side effects and its correlation with pharmacogenetic data
during sunitinib therapy need further studies.
Acknowledgements and funding
We thank Katarzyna Szamotulska and Magdalena Rosinska for statistical
assistance; and Dr Hanna Kosela for linguistic assistance. We thank Pfizer for
unrestricted educational grant for Polish Clinical GIST Registry. This work was
supported by the Polish Ministry of Science grant No NN402 2092 35.
Author details
1Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria
Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,
Warsaw, Poland. 2Pfizer Poland, Warsaw, Poland. 3Department of Biology and
Genetics, Medical University of Gdansk, Gdansk, Poland. 4GreaterPoland
Oncological Center, Poznan, Poland. 5Department of General Surgery,
Jagiellonian University, Medical Faculty, Cracow, Poland. 6Department of
Biostatistics, Institute of Mother and Child, Warsaw, Poland. 7Laboratory of
Experimental Oncology and Department of General Medical Oncology, KU
Leuven and University Hospital, Leuven, Belgium. 8Department of Radiology,
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,
Warsaw, Poland. 9Department of Gastrointestinal Tumors, Maria Sklodowska-
Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
10Department of Molecular Biology, Maria Sklodowska-Curie Memorial
Cancer Center and Institute of Oncology, Warsaw, Poland.
Authors’ contributions
Study concepts: PR, EB, AW, JK, ZIN, IL, JL. Study design: PR, AW, CO, IL, JL.
Data acquisition: PR, EB, AK, TŚ, SF, JK, IŁ, WM, CO, AW, UG, ZIN. Data analysis
and interpretation: PR, EB, IŁ, MB, EM, KW, AW, UG, JS, JL. Statistical analysis:
PR, IL, EM. Manuscript preparation: PR, AW, JL, MB, IŁ. Manuscript review: PR,
EB, AK, TŚ, SF, JK, IŁ, MB, WM, CO, EM, KW, AW, UG, ZIN, JS, JL. All authors
read and approved the final manuscript.
Competing interests
P. Rutkowski, C. Osuch, Z. Nowecki and A. Wozniak have received honoraria
and travel grants form Novartis, P. Rutkowski served in advisory board for
Novartis, J. Kroc is employed by Pfizer; P.Rutkowski and Z. Nowecki have
received honoraria and travel grants from Pfizer.
Received: 27 November 2011 Accepted: 22 March 2012
Published: 22 March 2012
References
1. Demetri GD, von Mehren M, Blanke CD, Blanke CD, Van den Abbeele AD,
Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M,
Table 6 Relationship between VEGFA/VEGFR2 gene
polymorphisms and sunitinib-induced hypothyroidism
grade ≥2.Statistically significant correlations are marked
in bold
Polymorphism Reference/risk
genotype
OR 95%CI p
value
VEGFA
rs699947 (C >
A)
CC ® AC ® AA 2.38 0.82 - 6.99 0.125
rs833061 (T >
C)
TT vs CT + CC 10.00 1.07 -
466.60
0.041
rs3025039 (C >
T)
CC vs CT + TT 10.50 1.42 -
117.40
0.015
rs2010963 (G >
C)
GG vs CG + CC 1.29 0.22 - 9.62 1.000
VEGFR2 (= KDR)
rs1531289 (A >
G)
GG vs AG + AA 1.60 0.33 - 8.29 0.758
rs1870377 (T >
A)
TT ® AT ® AA 0.74 0.19 - 2.64 0.822
CI confidence interval, OR odds ratio
Rutkowski et al. BMC Cancer 2012, 12:107
http://www.biomedcentral.com/1471-2407/12/107
Page 7 of 9
Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B,
Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and
safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
New Engl J Med 2002, 347:472-480.
2. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van
Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I:
Progression-free survival in gastrointestinal stromal tumours with high-
dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
3. Joensuu H: Gastrointestinal stromal tumor (GIST). Ann Oncol 2006,
17(Suppl 10):x280-x286.
4. Rutkowski P, Debiec-Rychter M, Ruka W: Gastrointestinal stromal tumors:
key to diagnosis and choice of therapy. Mol Diagn Ther 2008,
12(3):131-143.
5. Rutkowski P, Nowecki ZI, Dębiec-Rychter M, Grzesiakowska U, Michej W,
Woźniak A, Siedlecki JA, Limon J, Jerzak vel Dobosz A, Kąkol M, Osuch C,
Ruka W: Predictive factors for long term effects of imatinib therapy in
patients with inoperable/metastatic CD117(+) gastrointestinal stromal
tumors (GISTs). J Canc Res Clin Oncol 2007, 133:589-597.
6. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM: SU11248 inhibits
KIT and platelet-derived growth factor receptor beta in preclinical
models of human small cell lung cancer. Mol Cancer Ther 2003, 2:471-478.
7. O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM,
Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ,
Heinrich MC, Cherrington JM: SU11248 is a novel FLT3 tyrosine kinase
inhibitor with potent activity in vitro and in vivo. Blood 2003,
101:3597-3605.
8. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK,
Brassard JA, O’Farrell AM, Cherrington JM, Pryer NK: SU11248 inhibits
tumor growth and CSF-1R-dependent osteolysis in an experimental
breast cancer bone metastasis model. Clin Exp Metastasis 2003,
20:757-766.
9. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE,
Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG,
Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S,
McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a
novel tyrosine kinase inhibitor targeting vascular endothelial growth
factor and platelet-derived growth factor receptors: determination of a
pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003,
9:327-337.
10. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH,
Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M: An orally administered
multitarget tyrosine kinase inhibitor, SU11248, is a novel potent
inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin
Endocrinol Metab 2006, 91:4070-4076.
11. Maki RG, Fletcher JA, Heinrich MC, Morgan JA, George S, Desai J, Scheu K,
Fletcher CD, Baum C, Demetri GD: Results from a continuation trial of
SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal
stromal tumor (GIST). J Clin Oncol 2005, 23(16S):Abs 9011..
12. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH,
Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J,
Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and
safety of sunitinib in patients with advanced gastrointestinal stromal
tumour after failure of imatinib: A randomised controlled trial. Lancet
2006, 368:1329-1338.
13. George S, Blay JY, Casali PG, Le Cesne A, Morgan JA, Pokela J, Quigley MT,
Tassell V, Baum CM, Demetri GD: Continuous daily dosing (CDD) of
sunitinib malate (SU) compares favorably with intermittent dosing in pts
with advanced GIST. J Clin Oncol 2007, 25(18S):Abs 10015..
14. Reichardt P, Kang YK, Ruka W, Seddon B, Baum CM, Demetri GD:
Subpopulation analyses in a worldwide treatment-use trial of sunitinib
(SU) in GIST patients (pts) with resistance or intolerance to prior
imatinib (IM) therapy. J Clin Oncol 2007, 25(18S):Abs 10022..
15. Levy BI: Blood pressure as a potential biomarker of the efficacy
angiogenesis inhibitor. Ann Oncol 2009, 20:200-203.
16. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS,
Motzer RJ: Hypertension as a Biomarker of Efficacy in Patients With
Metastatic Renal Cell Carcinoma Treated With Sunitinib. J Natl Cancer Inst
2011, 103:763-773.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L,
Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG:
New guidelines to evaluate the response to treatment in solid tumors. J
Natl Cancer Inst 2000, 92:205-216.
18. Cancer therapy evaluation program: Common terminology criteria for
adverse events version 3.0 (CTCAE). Bethesda, MD: National Cancer
Institute; 2003, (Available at http://ctep.cancer.gov/forms/CTCAEv3.pdf).
19. Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, Sygut J,
Chosia M, Rys J, Urbanczyk K, Kruszewski W, Sowa P, Siedlecki J, Debiec-
Rychter M, Limon J, on behalf of Polish Clinical GIST Registry: Prognostic
value of KIT/PDGFRA mutations in gastrointestinal stromal tumours
(GIST): Polish Clinical GIST Registry experience. Ann Oncol 2011.
20. Blay J-Y: Pharmacological management of gastrointestinal stromal
tumours: an update on the role of sunitinib. Ann Oncol 2010, 21:208-215.
21. Dudeck O, Zeile M, Reichardt P, Pink D: Comparison of RECIST and Choi
criteria for computed tomographic response evaluation in patients with
advanced gastrointestinal stromal tumor treated with sunitinib. Ann
Oncol 2011, 22(8):1828-1833.
22. Yoon DH, Ryu M-H, Ryoo B-Y, Beck M, Choi D-R, Cho Y, Lee Y-L, Chang H-
M, Kim TW, Kang Y-K: Sunitinib as a second-line therapy for advanced
GISTs after failure of imatinib: relationship between efficacy and tumor
genotype in Korean patients. Invest New Drugs 2011, doi 10.1007/s10637-
010-9593-1 S2.
23. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D,
Town A, McKinley A, Ou W-B, Fletcher JA, Fletcher CDM, Huang X,
Cohen DP, Baum CM, Demetri GD: Primary and Secondary Kinase
Genotypes Correlate With the Biological and Clinical Activity of Sunitinib
in Imatinib-Resistant Gastrointestinal Stromal Tumor. J Clin Oncol 2008,
26:5352-5359.
24. Demetri GD, Heinrich MC, Fletcher JA, Fletcher CDM, Van den Abbeele AD,
Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL,
Huang X, Cohen DP, Baum CM, Maki RG: Molecular target modulation,
imaging, and clinical evaluation of gastrointestinal stromal tumor
patients treated with sunitinib malate after imatinib failure. Clin Cancer
Res 2009, 15(18):5902-5909.
25. Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD, Maki RG,
Singer S, Dematteo RP, Besmer P, Antonescu CR: Mechanisms of sunitinib
resistance in gastrointestinal stromal tumors harboring KITAY502-3ins
mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer
Res 2009, 15(22):6862-6870.
26. Nishida T, Takahashi T, Nishitani A, Doi T, Shirao K, Komatsu Y, Nakajima K,
Hirota S: Sunitinib-resistant gastrointestinal stromal tumors harbor cis-
mutations in the activation loop of the KIT gene. Int J Clin Oncol 2009,
14(2):143-149.
27. DiNitto JP, Deshmukh GD, Zhang Y, Jacques SL, Coli R, Worrall JW, Diehl W,
English JM, Wu JC: Function of activation loop tyrosine phosphorylation
in the mechanism of c-Kit auto-activation and its implication in sunitinib
resistance. J Biochem 2010, 147(4):601-609.
28. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP,
English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M,
Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR,
Marshall AG, Zhang HM, Demetri GD: KIT kinase mutants show unique
mechanisms of drug resistance to imatinib and sunitinib in
gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 2009,
106(5):1542-1547.
29. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B,
Leversha MA, JeVrey PD, Desantis D, Singer S, Brennan MF, Maki RG,
DeMatteo RP: Acquired resistance to imatinib in gastrointestinal stromal
tumor occurs through secondary gene mutation. Clin Cancer Res 2005,
11(11):4182-4190.
30. Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU,
Heinicke T, Speidel N, Pietsch T, Buettner R, Pink D, Reichardt P,
Hohenberger P: Polyclonal evolution of multiple secondary KIT mutations
in gastrointestinal stromal tumors under treatment with imatinib
mesylate. Clin Cancer Res 2006, 12(6):1743-1749.
31. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA,
Dychter SS, Larsen PR, Demetri GD, Alexander EK: Hypothyroidism after
sunitinib treatment for patients with gastrointestinal stromal tumors.
Ann Intern Med 2006, 145(9):660-664.
32. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P,
Schoeffski P: The clinical implications of sunitinib-induced
hypothyroidism: a prospective evaluation. Br J Cancer 2008, 99:448-454.
Rutkowski et al. BMC Cancer 2012, 12:107
http://www.biomedcentral.com/1471-2407/12/107
Page 8 of 9
33. Ruka W, Rutkowski P, Nowecki Z, Dziewirski W: Emergency surgery due to
complications during molecular targeted therapy in advanced
gastrointestinal stromal tumors (GIST). Ann Surg Oncol 2008, 15(Suppl
2):27, abstr 82.
34. Rutkowski P, Ruka W: Emergency surgery in the era of molecular
treatment of solid tumors. Lancet Oncol 2009, 10(2):157-163.
35. Van Der Graaf WT, Blay JY, Chawla SP, Kim D, Nguyen BB, Casali PG,
Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H,
Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji M, Dei Tos AP,
Hohenberger P: PALETTE: A randomized, double-blind, phase III trial of
pazopanib versus placebo in patients (pts) with soft-tissue sarcoma
(STS) whose disease has progressed during or following prior
chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072). J
Clin Oncol 2011, , Suppl: 29, abstr LBA10002.
36. Zhu X, Stergiopoulos K, Wu S: Risk of hypertension and renal dysfunction
with an angiogenesis inhibitor sunitinib: systematic review and meta-
analysis. Acta Oncol 2009, 48(1):9-17.
37. Ravaud A, Sire M: Arterial hypertension and clinical benefit of sunitinib,
sorafenib and bevacizumab in first and second-line treatment of
metastatic renal cell cancer. Ann Oncol 2009, 20:966-967.
38. Szmit S, Langiewicz P, Zołnierek J, Nurzyński P, Zaborowska M, Filipiak KJ,
Opolski G, Szczylik C: Hypertension as a predictive factor for survival
outcomes in patients with metastatic renal cell carcinoma treated with
sunitinib after progression on cytokines. Kidney Blood Press Res 2011.
39. Bono P, Rautiola J, Utriainen T, Joensuu H: Hypertension as predictor of
sunitinib treatment outcome in metastatic renal cell carcinoma. Acta
Oncol 2011, 50(4):569-73, Epub 2011 Jan 5.
40. Hood JD, Meininger CJ, Ziche M, Granger HJ: VEGF upregulates ecNOS
message, protein, and NO production in human endothelial cells. Am J
Physiol 1998, 274(3, pt 2):H1054-H1058.
41. van der Veldt AA, de Boer MP, Boven E, Eringa EC, van der Eertwegh AJ,
van Hinsbergh VW, Smudlers YM, Serne EH: Reduction in skin
microvascular density and changes in vessel morphology in patients
treated with sunitinib. Anticancer Drugs 2010, 21(4):439-446.
42. Vaziri SA, Kim J, Ganapathi MK, Ganapathi R: Vascular endothelial growth
factor polymorphisms: role in response and toxicity of tyrosine kinase
inhibitors. Curr Oncol Rep 2010, 12:102-108.
43. Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, Dreicer R,
Ganapathi MK, Ganapathi R: Association of VEGF and VEGFR2 single
nucleotide polymorphisms with hypertension and clinical outcome in
metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Cancer 2011, doi: 10.1002/cncr.26491.
44. Schneider BP, Radovich M, Miller KD: The role of vascular endothelial
growth factor genetic variability in cancer. Clin Cancer Res 2009,
15:5297-5302.
45. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J,
Figg WD: The role of vascular endothelial growth factor SNPs as
predictive and prognostic markers for major solid tumors. Mol Cancer
Ther 2009, 8:2496-2508.
46. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A,
Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA,
Cobleigh M, Shenkier T, Edgerton S, Miller KD, ECOG 2100: Association of
vascular endothelial growth factor and vascular endothelial growth
factor receptor-2 genetic polymorphisms with outcome in a trial of
paclitaxel compared with paclitaxel plus bevacizumab in advanced
breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678.
47. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM:
Cellular changes in normal blood capillaries undergoing regression after
inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006, 290:
H547-H559.
48. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR,
Norberg SM, O’Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G,
Joho S, Springer ML, Kuo CJ, McDonald DM: VEGF-dependent plasticity of
fenestrated capillaries in the normal adult microvasculature. Am J Physiol
Heart Circ Physiol 2006, 290:H560-H576.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/12/107/prepub
doi:10.1186/1471-2407-12-107
Cite this article as: Rutkowski et al.: The outcome and predictive factors
of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST)
after imatinib failure - one institution study. BMC Cancer 2012 12:107.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rutkowski et al. BMC Cancer 2012, 12:107
http://www.biomedcentral.com/1471-2407/12/107
Page 9 of 9
